Connective tissue diseases
Conditions
Interventions
Anti-osteoporosis Treatment Group (Calcium Supplements + Vitamin D + Bisphosphonates / Denosumab):None
Basic Treatment Group (Calcium Supplements + Vitamin D ):None
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 80 years, regardless of gender; 2. Meeting the diagnostic criteria for various CTD diseases (such as Primary Sjögren's Syndrome 2002 International Classification Criteria or 2016 ACR/EULAR Classification Criteria; Mixed Connective Tissue Disease Alarcón-Segovia criteria or Kahn criteria; Rheumatoid Arthritis 2010 ACR/EULAR Classification Criteria; Inflammatory Myopathy Bohan/Peter classification criteria; Systemic Lupus Erythematosus 2012 SLICC criteria or 2019 ACR/EULAR classification criteria); 3. Started using glucocorticoids [>=7.5 mg/day of prednisone (or equivalent)] along with basic treatment drugs (calcium, vitamin D) within the past 2 weeks, or glucocorticoids [>=7.5 mg/day of prednisone (or equivalent)] with basic treatment (calcium, vitamin D) and anti-osteoporosis drugs (bisphosphonates, zoledronic acid, or denosumab); 4. Baseline bone mineral density DXA scan (lumbar spine L1-L4 or hip): T-score between -1.0 and -2.5 (osteopenia).
Exclusion criteria
Exclusion criteria: 1. Combined hyperparathyroidism, Paget's disease of bone, osteomalacia; 2. Use of other anti-osteoporosis drugs (such as raloxifene, teriparatide); 3. Participation in any clinical trial within 3 months prior to screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Osteoporosis Progression Rate;Incidence of New-Onset Fractures; | — |
Secondary
| Measure | Time frame |
|---|---|
| Lumbar Spine BMD Decline Rate;Hip BMD Decline Rate; | — |
Countries
China
Contacts
Public ContactZhao Like
Beijing Hospital
Outcome results
None listed